Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 335 shares, an increase of 40.8% from the December 31st total of 238 shares. Based on an average daily trading volume, of 7,116 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 7,116 shares, the days-to-cover ratio is currently 0.0 days.

Alterity Therapeutics Stock Performance

ATHE stock opened at $3.17 on Friday. The company has a fifty day moving average of $3.30 and a 200-day moving average of $4.17. Alterity Therapeutics has a one year low of $2.52 and a one year high of $7.00.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ATHE shares. Canaccord Genuity Group started coverage on shares of Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Alterity Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATHE. Greenleaf Trust purchased a new position in shares of Alterity Therapeutics during the 2nd quarter worth approximately $70,000. Citadel Advisors LLC purchased a new position in Alterity Therapeutics in the third quarter worth $83,000. HB Wealth Management LLC acquired a new stake in Alterity Therapeutics in the third quarter valued at $220,000. Finally, Twin Lakes Capital Management LLC lifted its holdings in Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after acquiring an additional 133,333 shares during the period. Institutional investors and hedge funds own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.